Emerging Infections Programs

 

The purpose of the Emerging Infections Programs (EIP) is to assist in local, state, and national efforts to prevent, control, and monitor the public health impact of infectious diseases. The EIP cooperative agreement was formed in 1995 as a key component of CDCs national strategy to address and reduce emerging infectious disease (EID) threats. The EIP is a population-based network of state health agencies and their collaborators, including (but not limited to) academic institutions, local health departments, public health and clinical laboratories, infection control professionals, and healthcare providers. The network plays a critical role in conducting surveillance and applied epidemiologic and laboratory research, implementing and evaluating prevention and intervention projects, and responding quickly to new infectious disease issues. The unique strength of the EIP lies in the networks ability to quickly translate surveillance and research activities into informed policy and public health practice.

Active 93.317 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants Not applicable. Public Health Service Act Sections 301(a)[42 U.S.C. 241(a)], 317(k)(1)[42 U.S.C. 247b(k)(1)], and 317(k)(2)[42 U.S.C. 247b(k)(2)], as amended. Eligibility is limited to State governments (specifically, state health departments) or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Marianna Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau). The EIP infrastructure depends on a direct relationship with public health agencies that have sufficient legal authority and responsibility to perform public health surveillance and response activities. The network must also consist of definitive populations large enough to adequately determine disease burden, evaluate large scale interventions, and impact public health policy decisions. Beneficiaries of this program include State and local health departments, the District of Columbia, U.S. Territories, and the general public. Not applicable. Preapplication coordination is required. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. This program is excluded from coverage under 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards. Applications that are complete and responsive will be evaluated for scientific and technical merit by an appropriate Objective Review Panel (ORP) in accordance with CDC ORP review policies and procedures. CDC will not review incomplete and non-responsive applications. Complete and responsive applications will undergo a ORP review process, receive a written critique and be scored according to the published review criteria. Successful applicants will receive a Notice of Award (NOA) from the CDC Office of Grants Services. The NOA shall be the only binding, authorizing document between the recipient and CDC. The NOA will be signed by an authorized Grants Management Officer. Initial award provides funds for the first budget period (usually 12 months) and the NOA will indicate support recommended for the remainder of the project period, allocation of Federal funds by budget categories, and special conditions, if any. Once competing applicants have been selected by the ORP review process for the first year of funding in the project period, those selected will be eligible to submit annual non-competitive continuation applications for each successive budget period of the project period. Contact the headquarters or regional location, as appropriate for application deadlines From 90 to 120 days. Not applicable. From 120 to 180 days. Awards under this Program are typically issued for 1- to 5-year project periods. Renewals at the end of each project period are expected to be made available via publishing of a new/continuation NOFO with a complete application and review/award process as described above. Annual renewals within an awarded multi-year project period are made via a non-competitive process and are subject to the availability of funding. Applications are reviewed against specific Evaluation Criteria published in the Notice of Funding Opportunity for this program. Evaluation Criteria in the most recently published NOFO include: (1) capacity to perform core functions of an EIP, (2) proposed operational plan for carrying out the specific objectives of the program, and (3) measures of effectiveness. Recipients may only expend funds for reasonable program purposes, including personnel, travel, supplies, and services, such as contractual. Funding under this program will support activities that fall within the following general activities: (1)active surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) flexible response to public health emergencies. Activities: (1) address issues that the EIP network is particularly suited to investigate; (2) maintain sufficient flexibility for emergency response and new problems as they arise; (3) develop and evaluate public health interventions to inform public health policy and treatment guidelines; (4) incorporate training as a key function; and (5) prioritize projects that lead directly to the prevention of disease (http://wwwlink.cdc.gov/ncezid/dpei/eip). Performance Reports: Annual Federal Financial Reports (FFR) and performance/progress reports are required. Final FFRs and performance reports are required. Other reporting may be required and will be outlined in the NOFO or the Notice of Award. Not applicable. In accordance with 2 CFR ?200, as codified in 45 CFR ?75, there is a 3-year record retention requirement; records shall be retained beyond the 3-year period if final audit has not been done or findings resolved. Property records must be retained in accordance with HHS Grants Policy Statement requirements. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Financial assistance is provided for a 12-month budget period with a period of performance of up to five years subject to the availability of funds and satisfactory progress of the recipient. Notice of Award None/Not specified. Rainy Henry
1600 Clifton Road NE, MS-C18
Atlanta, GA 30329 US
roa3@cdc.gov
Phone: 404-639-6146 http://www.cdc.gov 75-0949-0-1-550 (Cooperative Agreements) FY 22$62,105,005.00; FY 23 est $65,528,124.00; FY 24 est $66,000,000.00; FY 21$60,179,667.00; FY 20$73,122,950.00; FY 19$44,837,943.00; FY 18$26,055,351.00; FY 17$20,362,615.00; FY 16$65,697.00; - Awards typically range between approx. $1.1M to 8.8M annually, with an average award of $6.5M. Regulations governing this program are published in the specific Notice of Funding Opportunity and identified on the notices of award. Regulations are also published under 45 CFR 75 and also HHS Grants Policy Statement at https://www.hhs.gov/sites/default/files/grants/grants/policies-regulations/hhsgps107.pdf. Fiscal Year 2016 Activities for this program fall into the following general categories: (1) active surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) flexible response to public health emergencies. Activities: (1) address issues that the EIP network is particularly suited to investigate; (2) maintain sufficient flexibility for emergency response and new problems as they arise; (3) develop and evaluate public health interventions to inform public health policy and treatment guidelines; (4) incorporate training as a key function; and (5) prioritize projects that lead directly to the prevention of disease (http://wwwlink.cdc.gov/ncezid/dpei/eip). The EIPs have proved to be a national resource for conducting active, population-based surveillance and special studies for invasive bacterial diseases, foodborne pathogens, healthcare associated infections (HAIs), influenza, and many other infectious diseases. The network has been instrumental in measuring the impact of the 7-valent pneumococcal conjugate vaccine, informing and evaluating treatment guidelines for Group B Streptococcus, estimating the burden of foodborne illness, documenting the emergence of community-associated methicillin-resistant Staphylococcus aureus, and monitoring the safety of the 2009 H1N1 vaccine as part of the influenza vaccine safety network
Fiscal Year 2020 Activities for this program fall into the following general categories: (1) active surveillance; (2) applied public health epidemiologic and laboratory activities; (3) implementation and evaluation of pilot prevention/intervention projects; and (4) flexible response to public health emergencies. Activities: (1) address issues that the EIP network is particularly suited to investigate; (2) maintain sufficient flexibility for emergency response and new problems as they arise; (3) develop and evaluate public health interventions to inform public health policy and treatment guidelines; (4) incorporate training as a key function; and (5) prioritize projects that lead directly to the prevention of disease (http://wwwlink.cdc.gov/ncezid/dpei/eip). Activities include conducting active, population-based surveillance and special studies for invasive bacterial diseases, foodborne pathogens, healthcare associated infections (HAIs), influenza, and many other infectious diseases.